Phathom Pharmaceuticals Appoints Martin J. Gilligan as Chief Commercial Officer
Phathom Pharmaceuticals, Inc. (PHAT)
Last phathom pharmaceuticals, inc. earnings: 3/19 08:31 am
Check Earnings Report
Company Research
Source: Business Wire
Martin Gilligan joins from Celgene Corporation where he led marketing, market access and business development for the Inflammation & Immunology Franchise FLORHAM PARK, N.J.--(BUSINESS WIRE)--Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced the appointment of Martin J. Gilligan as Chief Commercial Officer. Mr. Gilligan most recently was Corporate Vice President at Celgene Corporation, where he led marketing, market access and business development for Celgene’s Inflammation and Immunology Franchise. He held key leadership roles in the launch and growth of OTEZLA® through its sale to Amgen for $13.4 billion.“Martin brings deep biopharmaceutical sales, marketing and market access expertise, and we’re thrilled to have him join our executive team as we prepare for the potential commercialization of vonoprazan,” said Terrie Curran, Chief Executiv
Show less
Read more
Impact Snapshot
Event Time:
PHAT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHAT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHAT alerts
High impacting Phathom Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
PHAT
News
- Phathom's Voquezna: A Breakthrough Drug Facing Marketing Challenges [Seeking Alpha]Seeking Alpha
- Amoxicillin Market Research Report 2024: Combination Therapies and Immunotherapy Trends Shaping Future Landscape - Global Long-term Forecast to 2028 and 2033 [Yahoo! Finance]Yahoo! Finance
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)PR Newswire
- Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.MarketBeat
- Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.MarketBeat
PHAT
Earnings
- 8/8/24 - Beat
PHAT
Sec Filings
- 8/22/24 - Form SC
- 8/19/24 - Form 8-K
- 8/19/24 - Form 424B5
- PHAT's page on the SEC website